Company / R&D Expense
Oric Pharmaceuticals, Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$109.8M
FY2025
5-year range
$56.9M / $114.1M
FY2021-FY2025
Trend
-3.7%
vs FY2024
Sector context
#135 of 210
Health Care
What the data says
At $110M, Oric Pharmaceuticals, Inc.'s r&d expense ranks #135 of 210 in the Health Care sector. Improved from $85M to $110M over the past 2 years.
Based on SEC 10-K filings.
$110M in FY2025 with a 5-year CAGR of +25.0%.
Improved from $85M to $110M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +21.2%
- 5-Year CAGR
- +25.0%
- 10-Year CAGR
- -
Sector benchmark
#135 of 210 in Health CareTop 64% of 210This company $109.8M Sector average $644.1M
▼
-83.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +25.0%, indicating consistent growth.
- In FY2025, r&d expense decreased 3.7% year-over-year.
- Ranks #135 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 5.96 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $109.8M | -3.7% |
| FY2024 | $114.1M | +33.9% |
| FY2023 | $85.2M | +38.1% |
| FY2022 | $61.7M | +8.5% |
| FY2021 | $56.9M | +58.3% |
| FY2020 | $35.9M | +57.2% |
| FY2019 | $22.8M | +20.1% |
| FY2018 | $19.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026